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Abstract
Interest in the placebo effect of medicines has developed from the use of placebo treatments as controls in clinical trials into 
a whole new area of research around how placebos fit into a psychosocial model of therapeutics. The large placebo effect 
associated with cough medicines is both a problem and an opportunity for researchers: a problem for clinical trials on new 
actives as the active must beat the large placebo effect, and an opportunity for harnessing the placebo effect to produce effec-
tive cough medicines without any pharmacologically active ingredient. This review discusses the mechanisms associated 
with the placebo effect of cough medicines and distinguishes between a ‘perceived placebo effect’ and a true ‘placebo effect’. 
The efficacy of sweeteners in cough syrups is discussed as well as viscosity, mucoadhesion, and flavoring. The complexity 
of modern cough medicines is demonstrated by an example of a medicine which contains one active ingredient, and eight-
een excipients which provide a complex and intense sensory experience to enhance the placebo effect and complement the 
pharmacological activity of the medicine.
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Introduction
Cough is one of the most common and distressing of 
symptoms, yet at present, there is little to offer patients to 
relieve cough apart from cough syrups which are effective 
because of a powerful placebo effect [1, 2]. Codeine was 
once deemed a powerful antitussive for all types of cough 
because of its presumed depressant effect on cough control 
at the level of the brainstem but doubts have been raised on 
its efficacy and it is no longer considered a ‘gold standard’ 
antitussive [3]. Much progress is being made on the periph-
eral mechanism of cough at the level of sensory nerves in the 
airway but clinical trials on some of the best candidates for 
a new cough medicine are proving difficult because of side 
effects [4]. The placebo effect in cough therapy is both a gift 
and a problem to those working on treatments for cough. It 
is a gift because cough is so susceptible to a placebo effect 
with one review reporting that up to 85% of the efficacy of 
cough medicines is due to a placebo effect [5]. It is also a 
problem to researchers as with such a large placebo effect 
it is difficult to demonstrate that any new cough medicine 
is superior to placebo treatment in cough clinical trials. The 
magnitude of the placebo effect in the treatment of cough 
with inhaled steroids has recently been highlighted and the 
authors conclude that clinicians should be cautious about 
attributing the response of patients on inhaled steroids to 
anything more than a placebo effect [6]. This review will 
discuss the significance of the placebo effect in the develop-
ment of new cough treatments and its importance in cough 
clinical trials.
What is a Placebo and a Placebo Effect?
The term ‘placebo’ originates as a Latin term and means 
‘I shall please’ [7]. Before the introduction of codeine as a 
therapy for cough in the nineteenth century [8], all cough 
medicines could be considered as placebo treatments that 
were meant to please patients even though physicians and 
patients may have believed that they had active properties 
above that of a placebo treatment. An early edition of the 
Merck’s manual [9] lists 61 treatments for cough, including 
carbolic acid, alcohol, cannabis, indica, creosote, morphine, 
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potassium bromide, sandalwood oil, and zinc sulfate, and 
describes cod-liver oil as the most useful of all remedies in 
cough. All of these cough medicines are likely to have had 
some beneficial placebo effect and reduced the severity of 
cough, and that is why they were regularly prescribed by 
physicians and regularly pleased patients. When patients are 
given any cough medicine, they usually feel better and the 
severity of their cough is reduced but it is difficult to sepa-
rate out any pharmacological effect of the medicine from any 
placebo effect unless the treatment is compared with a pla-
cebo treatment in a double-blind randomized clinical trial.
Perceived and True Placebo Effects
The efficacy of any cough medicine depends on two factors: 
firstly the efficacy of the pharmacologically active medi-
cine such as codeine or dextromethorphan and secondly the 
placebo effect of the treatment. When discussing the pla-
cebo effect, it is important to separate the ‘perceived pla-
cebo effect’ from the ‘true placebo effect’. This distinction 
was first put forward by Ernst in 1995 [10] and was later 
extended to explain the placebo effect of cough medicines 
[5, 11].
The perceived placebo effect is the total response to pla-
cebo treatment seen in a clinical trial, and the perceived 
placebo effect is made up of three components as illustrated 
in Fig. 1. The ‘physiological effect’ of a cough treatment is 
the effect due to the taste of the medicine and is related to 
stimulation of salivation and mucus secretions that soothe 
and lubricate the airway, and may also be related to a spe-
cific effect of sweet taste as discussed below. The physiologi-
cal effect of a cough medicine is utilized in cough syrups as 
a major component of their efficacy, and this physiological 
effect is not present or minimal in cough medicines formu-
lated as a tablet or capsule. The ‘non-specific’ components 
of any treatment are related to factors such as natural recov-
ery of the patient, and regression to a mean value of cough 
severity, as patients are generally recruited into a clinical 
trial with severe symptoms and these measures can only 
regress towards a mean value. The true placebo effect can 
be considered as the psychological effects of the treatment 
that lead to a reduction in cough severity. The true placebo 
effect was first of interest in clinical trials but interest in 
this phenomenon has evolved into a psychosocial model 
which incorporates a general interaction of the patient to 
their environment and how they respond to psychological 
mechanisms such as conditioning, expectation, reward, 
and anxiety reduction, and how these can be modulated by 
desire, motivation, and memory [12].
As can be seen in Fig. 1, the component of the true pla-
cebo response is part of the perceived placebo response that is 
measured in clinical trials. In order to determine the magnitude 
of the true placebo response it is necessary to conduct a clini-
cal trial with a ‘no treatment’ group and subtract the response 
of the no treatment group from the response of the perceived 
placebo group. The physiological response, which is also con-
tained in the perceived placebo response, can be minimized by 
using a tablet formulation as the treatment rather than a syrup. 
Clinical trials rarely contain a no treatment group and only 
one study on acute cough associated with common cold has 
been performed with this design [13]. In this study the placebo 
treatment consisted of a capsule containing vitamin E, which 
over the short duration of the measurement period for cough 
(15 min) would not have been absorbed to have any effect on 
cough. The effect of placebo treatment on cough frequency is 
illustrated in Fig. 2 which shows a marked reduction in cough 
frequency compared to no treatment. The small reduction in 
cough frequency associated with no treatment could be due to 
a demulcent effect as both groups were given 50 ml of water 
to drink even though the no treatment group did not need this 
water to swallow any capsule. The difference between the pla-
cebo treatment group and the no treatment group in this study 
gives us a measure of the true placebo effect and it indicates 
and demonstrates its significance in cough therapy.
Fig. 1  Efficacy of any cough syrup medicine in a clinical trial con-
sists of four components. Pharmacological related to the efficacy of 
the active ingredient. Physiological related to the demulcent effect. 
True placebo related to the sensory impact of the medicine and belief 
of the participant abut efficacy. Non-specific related to natural recov-
ery. The total efficacy of the placebo control treatment is the PER-
CEIVED PLACEBO EFFECT and it includes the TRUE PLACEBO 
EFFECT and the non-specific effect of natural recovery over the time 
period of the trial
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What Makes a Good Placebo Cough 
Medicine?
If placebo treatments are effective at treating cough why not 
enhance the placebo effect and use a placebo treatment as 
a commercial cough medicine? Issues around this approach 
are firstly those concerning the patient’s perception of the 
medicine and secondly the regulatory environment and 
claims that can be made for the medicine. Patients will not 
purchase or believe in a medicine that they know has no 
active component or which is referred to as a placebo, and 
regulatory authorities will not allow claims for cough medi-
cines composed only of flavoring and excipients. However, 
with publicity around clinical trials testing honey as a cough 
medicine [14–16] and negative reports about conventional 
antitussives such as dextromethorphan [17, 18], the public 
has become more convinced about the efficacy of simple 
linctus medicines containing honey and glycerol and these 
simple linctuses are now marketed with honey, glycerol, and 
sugar declared as active ingredient [19]. The great advantage 
of this type of medicine is that they are supported by pedia-
tricians as safe for children and they can be dosed frequently 
without any major risk of side effects. In developing a pow-
erful placebo cough medicine the following components of 
the medicine need to be considered.
Taste
Look in any pharmacy for a cough medicine and you will 
see that the great majority of those on sale are formulated as 
sweet viscous syrups. Viscous syrups formulated as a cough 
medicine are known as a linctus. This formulation of a cough 
medicine has evolved over thousands of years and is prob-
ably related to the properties of the first cough medicine, nat-
ural honey. Natural honey has been used as a cough medicine 
for thousands of years and it is still popular as a cough treat-
ment today [20]. Natural honey varies widely in its composi-
tion, color, and taste and it contains about 200 substances, 
including amino acids, vitamins, minerals, and enzymes, 
but it primarily contains sugar and water [20]. Sugars such 
as glucose, fructose, maltose, sucrose account for 95–99% 
of honey dry matter [20]. Honey was the first source of a 
sweetener for cough medicines but from the fifteenth cen-
tury onwards sugar cane and sugar beet started to provide a 
much cheaper and more readily available source of sugar for 
cough medicines especially as inverted sugar syrup, which 
is often referred to as artificial honey, because of its sweet-
ness and viscosity [21]. Natural honey has been shown to be 
just as effective as conventional pharmacological treatments 
[14, 22, 23], but it is likely to be the sweet taste of honey 
that is the major factor in its efficacy rather than any spe-
cific pharmacological property of the honey. A recent study 
comparing buckwheat honey with a matched Golden Syrup 
sweet placebo on treatment of nocturnal cough in children 
has reported that honey is superior to matched sweet placebo 
[16]. However, the blinding of the study was not confirmed 
with any patient questionnaire or other means, and therefore 
the results could still be explained as comparing one sweet 
placebo against another sweet placebo, rather than honey 
having any specific effect on cough.
Fig. 2  Change in median cough frequency over 15 min period after 
treatment with a placebo medicine (vitamin E capsule, n = 27) or 
no treatment (n = 27). Both groups took 50  ml of water. The small 
reduction in cough frequency seen in the no treatment group may 
be related to a demulcent effect of water. The magnitude of the true 
placebo effect can be estimated by subtracting the no treatment effect 
from the perceived placebo effect
Fig. 3  Gustatory effects on cough. Gustation is mediated by branches 
of the facial (VII), glossopharyngeal (IX), and vagus (X) cranial 
nerves that supply the taste buds of the tongue, these gustatory nerves 
relay in the nucleus tractus solitarius (NTS) in the brainstem. The 
NTS also serves as a relay for the vagal nerve fibers (X) that mediate 
the cough reflex. It is proposed that there may be some interaction (?) 
between these gustatory and cough pathways in the NTS that influ-
ences cough, perhaps by the mediation of endogenous opioids
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Sweet cough syrups have been proposed to act as anti-
tussives by sweet taste modulating the activity the nucleus 
tractus solitarius at the level of the brainstem as illustrated 
in Fig. 3 [2]. This hypothesis was tested using capsaicin 
induced cough in healthy subjects as a cough model and 
sweet but not bitter taste was shown to increase cough reflex 
thresholds [24, 25]. Sweet taste may therefore have a spe-
cific antitussive activity rather than just be a pleasing taste 
for the patient. This may also explain the traditional use of 
liquorice in the treatment of cough as the active constituent 
of liquorice, glycyrrhizin, is 20–50 times the sweetness of 
glucose weight for weight [26].
A sweet taste may be only one way of enhancing the 
placebo effect of a cough medicine as the placebo effect 
may also be related to the organoleptic sensory impact of 
the medicine, and for some patients, an unpleasant taste of 
a medicine indicates a powerful medicine [27]. Capsicum 
flavor provides a powerful taste to some cough medicines 
and may also act as a gustatory stimulus to increase mucus 
secretions in the airway [28, 29].
Cooling, Warming, and Tingling Effects
Cooling and warming agents are often added to cough medi-
cines to increase the sensory impact of the medicine and 
perhaps increase its placebo effect. Capsicum is a flavoring 
agent that is an extract of peppers and contains capsaicin 
which interacts with oral sensory trigeminal nerve endings 
to activate TRPV1 receptors to give a sensation of burning 
irritation and warmth [30]. Capsicum flavor gives a power-
ful hot taste to lozenges such as ‘Fisherman’s Friend’ which 
have been marketed for over one hundred years to treat 
respiratory conditions such as cough [31, 32]. Menthol is 
included in many cough syrups and lozenges to give a cool 
sensation and is referred to as either a flavoring agent or an 
active ingredient. Menthol acts on the TRPM8 receptor on 
sensory nerves in the oral cavity and airway to give a cool 
sensation [33–35]. Apart from providing a sensory impact 
to a cough medicine menthol may also have some specific 
antitussive properties [24, 36–38] and menthol is recognized 
as an antitussive by regulatory authorities such as the US 
Food and Drug Administration.
Capsicum and menthol have a long history as warming 
and cooling agents but they are now often replaced in cough 
medicines by new flavoring excipients such as cooling flavor 
539692T and hot mix flavor 538842T which are dissolved in 
propylene glycol and manufactured and marketed by special-
ized flavoring companies.
The placebo effect is influenced by the sensory impact of 
the cough medicine and this sensory impact can be enhanced 
by excipients that give a tingling sensation. Tingling flavor 
538723T is added to some cough medicines to provide this 
tingling sensation.
Viscosity
As mentioned above, most cough medicines are formu-
lated as viscous syrups. The viscosity of the medicine may 
have a sensory impact that enhances a placebo effect in 
two ways. Firstly, a viscous thick syrup may be perceived 
by the patient as a more powerful medicine than a watery 
medicine. Secondly, a viscous medicine will tend to stick 
to the oral mucosa and esophagus and provide a more pro-
longed sapid stimulus than a watery medicine. Viscous 
syrups such as honey provide a more prolonged sweet taste 
than sugar water as they tend to stick to the oral mucosa 
and teeth. High concentrations of glucose and other sug-
ars as well as inverted sugar will increase the viscosity of 
a cough medicine. Glycerol is a common component in 
cough medicines and it increases both the viscosity and 
the sweetness of the medicine [39]. The viscosity of cough 
medicines may be increased by addition of excipients such 
as carboxymethylcellulose sodium and carbomer, which 
can also act as coating agents to stick to the oral mucosa 
and prolong the sensory impact of flavors in the medicine 
[40].
Color
The placebo effect of medicines such as tablets is influ-
enced by the color of the tablet with red yellow and orange 
associated with a stimulant effect and blue and green 
associated with a tranquilising effect [41, 42]. Cough 
medicines are often colored and the most common colors 
are brown and red. The brown color often relating to the 
presence of a caramel flavor and the red color related to 
the addition of Ponceau 4R (E124). The brown and red 
colors may impart a sense of strength to the placebo effect 
although no published research has been found on the 
effect of color on the placebo effect of cough medicines.
Odor
No information has been found in the literature on the use 
of odors to enhance or trigger placebo effects in cough 
medicines, but since odors have a great capacity to evoke 
memory and to influence behavior and emotion [43], it 
is likely that the odor of a cough medicine will influence 
the placebo effect of the medicine. Odor-evoked memo-
ries are especially visceral because of the neuroanatomy 
of olfaction and they evoke more emotional and evoca-
tive recollections than memories triggered by any other 
sensation [43]. Odors may be an under utilized tool in 
enhancing the placebo effect of cough medicines. Most 
cough medicines have a medicinal odor or a menthol odor 
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and theses odors may trigger memory and influence the 
placebo effect. Large placebo effects have been reported 
for odors in aromatherapy, and a coffee-like scent which 
contains no caffeine can elicit a placebo effect and increase 
arousal [44, 45]
Belief
A conscious belief in the efficacy of a cough medicine is 
probably the most important factor in determining the mag-
nitude of the true placebo effect. The factors listed above—
taste, cooling, warming, tingling, viscosity, and color—all 
contribute to the sensory impact of the medicine and influ-
ence the perceived placebo effect, but if the patient does not 
believe in the efficacy of the medicine the sensory impact 
will have little if any influence on the true placebo effect. 
The sensory impact of the treatment can still provide a 
demulcent and soothing effect through stimulation of sali-
vation and mucus production but unless the patient believes 
in the efficacy of the medicine it will not have a true placebo 
effect.
The role of belief in the placebo effect has been discussed 
in detail by Evans in the book “Placebo. The Belief effect” 
[46], and a full discussion on the influence of belief on the 
placebo effect is beyond the remit of this review which is 
focussed on the role of belief in the efficacy of a cough 
medicine.
Belief in the efficacy of a cough medicine is influenced 
by many different factors which have been described as the 
“psychosocial context around the therapy” [12]. Some of 
these factors are illustrated in Fig. 4. Belief about any cough 
therapy will first depend on the context of the therapy: is 
the patient consulting a healthcare practitioner such as a 
doctor, nurse or pharmacist in order to receive therapy or 
are they purchasing an over-the-counter (OTC) medicine 
from a supermarket or pharmacy outlet on their own ini-
tiative to obtain a cough therapy? In the first instance, the 
doctor–patient relationship and belief in the expertise of the 
practitioner will influence belief in the prescribed therapy, 
and in the second instance, purchase of an OTC cough medi-
cine will be influenced by factors such as advertising claims, 
packaging, cost, previous experience, personal recommenda-
tions. The environment in which the therapy is prescribed or 
purchased will also influence belief as a prescribed therapy 
delivered in a famous research hospital by an eminent physi-
cian at great expense may influence belief about the efficacy 
of the therapy more than the belief associated with picking 
up a cheap OTC cough medicine from a supermarket. The 
placebo and the doctor–patient relationship has been dis-
cussed in detail by Benedetti [47] in terms of a new physi-
ology which explores the relationship between belief and 
neurobiological phenomena.
Does the Placebo Effect Confound Cough 
Clinical Trials?
The placebo effect may confound clinical trials on cough 
medicines because the placebo effect is of such a great mag-
nitude that it leaves little room for any pharmacologically 
active substance to influence cough. This understanding has 
come from a review on acute cough which quantified the 
placebo effect as contributing up to 85% of the efficacy of 
any treatment, with the pharmacologically active ingredient 
only contributing 15% of the benefit of the cough medicine 
[5]. However, it is important to take into consideration two 
factors when considering the large magnitude of the placebo 
effect described in the review. Firstly, all the studies used in 
the review to calculate the placebo effect were conducted on 
acute cough, and spontaneous recovery may make a large 
contribution to the perceived placebo effect in these studies. 
Secondly, the studies described in the review were mainly 
conducted using dextromethorphan and codeine as actives, 
and the efficacy of both of these antitussives on acute cough 
has been challenged [3, 17, 48]. The large perceived pla-
cebo effect reported by the review may be due to sponta-
neous recovery of subjects and the weak pharmacological 
efficacy of the actives. It is also important to consider that 
much more information is needed about the magnitude of 
the placebo effect in clinical trials, as in a meta-analysis on 
the placebo effect in clinical trials on analgesics it has been 
shown that there is a great variability in the magnitude of the 
placebo effect [49, 50]. With only one review article Eccles 
[5] assessing the magnitude of the perceived placebo effect 
in cough clinical trials, involving only eight clinical trials on 
cough, it is not possible to properly estimate the magnitude 
Fig. 4  Factors influencing patient belief about the efficacy of a cough 
medicine, in this example illustrating doctor–patient interaction
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of any true or perceived placebo effect in a cough clinical 
trial. It is not possible to determine if cough clinical trials 
are confounded by a large placebo effect and at present the 
main issue appears to be a lack of efficacy of the active com-
pounds tested as antitussives.
Voluntary Control of Cough
Cough is an unusual symptom in that it is under voluntary 
control [51]. Healthy subjects can cough and their cough 
is indistinguishable from a cough associated with an upper 
respiratory tract infection. Similarly cough associated with 
upper respiratory tract infection can be voluntarily sup-
pressed [52]. This voluntary control of cough can confound 
clinical trials that use any sort of cough count as an end-
point, as if subjects believe they are receiving an active 
cough medicine then they may be able to alter their cough 
response in accord with their beliefs and cough less. One 
could argue that any voluntary control of cough is not a pla-
cebo effect as the control of cough can be achieved without 
any placebo treatment but ‘belief’ is a major factor in deter-
mining the magnitude of any true placebo effect and it is 
difficult to separate between a conscious voluntary control of 
cough and the unconscious response to a placebo treatment. 
In the past, clinical trials on cough medicines have focussed 
on cough counts and the severity of cough as perceived by 
the patient but more recently there has been interest in ‘the 
urge-to-cough’ which is dependent on a sensation of airway 
irritation and which precedes any cough [53]. The urge-to-
cough has been shown to be influenced by placebo treat-
ment, indicating that whatever measure of cough is used in 
clinical trials it is still subject to a placebo effect [54].
Kinetics and Dynamics of Placebo Effect
A pharmacologically active cough medicine such as dex-
tromethorphan will have pharmacokinetic and pharmaco-
dynamic properties, and studies on its efficacy as a cough 
medicine will take these properties into consideration when 
deciding on which time points after dosing to measure its 
antitussive activity. The physiological effects of a placebo 
treatment such as a sweet cough syrup will also exhibit simi-
lar properties to a pharmacologically active medicine with 
characteristics such as time and intensity of peak response 
and rate of decline of response, which can generate pharma-
cokinetic parameters. There is little if any literature on the 
kinetics and dynamics of the placebo effect, although this 
topic was raised as an important aspect in clinical trials by 
Weiner and Weiner [42]. The true placebo effect, which is 
initiated by belief in the efficacy of the medicine, can also 
be considered to have pharmacokinetics even though there is 
nothing to be absorbed, distributed, metabolized or excreted, 
as the effects in the brain are eventually related to release 
and actions of neurotransmitters which do have pharmacoki-
netic properties [42]. At present the lack of knowledge about 
the pharmacokinetic and pharmacodynamics of the placebo 
effect is a possible confounding factor in the design of clini-
cal trials on cough medicines.
What Information Should be Given to the Patient 
About Placebo Treatment?
The patient information leaflet (PIL) is an important compo-
nent of the informed consent process of admitting patients 
into a clinical trial as the patient must be given all the rel-
evant information about the test therapy in order to make an 
informed opinion as to whether or not to participate in the 
clinical trial. The PIL usually describes possible benefits and 
adverse effects and risks associated with the active cough 
therapy but information about the placebo treatment is usu-
ally brief, incomplete and sometimes inaccurate [55]. The 
words used to describe the placebo treatment are often a 
description of a “dummy” pill or “inactive control medicine” 
that looks and tastes like the “real” medicine. No studies 
have been found in the literature on the information given in 
PIL in cough clinical trials. A study on the PIL information 
about placebos in clinical trials on acupuncture reports that 
how participants are told about placebos may influence the 
blinding of the study and the study outcome by influencing 
patient expectation [56].
Studies on the true placebo effect of cough therapy are 
often confounded by ethical considerations to tell the truth 
about the treatments and the purpose of the study. In a study 
to determine the magnitude of the true placebo effect of 
cough therapy in a clinical trial, vitamin E was used as a pla-
cebo therapy but the term “placebo” was not used in the PIL, 
which stated that the “The study is designed to investigate 
the effect of vitamin E on cough associated with the com-
mon cold” [13]. The effects of vitamin E treatment (placebo) 
on cough were compared to a “no treatment” group in order 
to determine the true placebo effect of therapy [13]. The 
study provided new information about the magnitude of the 
true placebo effect of cough therapy, but it can be criticized 
as using deception in the PIL, as the true aim of the study 
was not given in the PIL. Deception in the research on the 
placebo effect has been discussed in detail in a review article 
[57] and the authors discuss the use of “authorised decep-
tion” in placebo research where the participants are informed 
in the PIL that some form of deception may be used in the 
research [57].
Since placebos do have beneficial effects, a case has been 
made that much more information should be provided in the 
PIL about the positive benefits of placebo therapy and the 
placebo effect, and that lack of knowledge about the pla-
cebo effect in the PIL breaches the ethical obligations of 
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the researchers [58]. A case is made that there is substan-
tial knowledge about the effects of placebo treatment on the 
brain and especially on the analgesic effects of placebos but 
that this knowledge is not reflected in the informed consent 
procedures [58]. Informing clinical trial participants about 
the health benefits of placebos may be good clinical practice 
as regards a more accurate and comprehensive PIL, but it 
may influence participant expectations about the therapies 
used in the trial and bias the outcome of the trial. Exactly 
what information should be given about placebo treatments 
in PIL remains a controversial area for clinical researchers.
How Can the Placebo Effect be Utilized 
in the Development of New Cough 
Medicines?
Cough medicines have evolved over centuries to maximize 
the placebo effect by being formulated as sweet viscous 
syrups and this evolution is still in progress today as phar-
maceutical companies utilize new flavors and sensations to 
increase the impact of their OTC cough medicines. There is 
an ongoing research effort to develop new antitussive medi-
cines and most of these involve clinical trials on actives in 
tablet form [4, 59]. However, if these new active agents are 
eventually used commercially for the treatment of cough, the 
efficacy of the cough medicine would be greatly enhanced by 
formulating the medicine as a sapid sweet syrup in order to 
utilize a large placebo effect of treatment in addition to any 
pharmacological effect of the medicine.
The formulations of OTC cough medicines have evolved 
to provide powerful placebo effects by utilizing the effects 
of excipients and flavors. The composition of a current 
OTC cough medicine [60] is illustrated in Fig. 5, and it 
demonstrates that the ingredients provide a complex mix 
of sweeteners and flavors that enhance the placebo effect 
of the medicine. In this medicine the sweetness is provided 
by not one but four ingredients (glucose, glycerol, sucrose, 
and sucralose). The sugar content (glucose and sucrose) is 
898 mg/ml which translates into a dose of 36 g of sugar a 
day, and the sweetness is further enhanced with the inclusion 
of glycerol and sucralose (sucralose has a sweetening power 
of 300–1000 times that of sucrose [40]. The viscosity of the 
syrup is increased by the presence of glycerol and carbomer, 
and the carbomer also provides some mucoadhesive prop-
erties to the syrup to bind it to the oral mucosa. The nine 
flavors provide an intense and complex sensory impact with 
honey, lemon, and caramel flavors and cooling and warming 
sensations. This example of an OTC cough medicine demon-
strates how far these medicines have evolved to enhance the 
placebo effect and complement any pharmacological effect 
of the active ingredient for the benefit of the patient.
Conclusion
The first cough medicines such as honey had only a pla-
cebo effect but they were effective medicines that pleased 
patients. In order to determine the pharmacological activ-
ity of medicines, the double-blind placebo controlled clini-
cal trial method was developed and many cough medi-
cines were shown to have no more efficacy than a placebo 
treatment. The perceived placebo effect in cough studies 
has been shown to consist of three components: a physi-
ological effect related to the taste of the medicine, a non-
specific effect related to natural recovery, and a true pla-
cebo effect related to belief in the efficacy of the medicine. 
The magnitude of the perceived placebo response has been 
shown to be up to 85% in some cough clinical trials, and 
this may confound the conduct of cough clinical studies 
but it is an advantage in developing OTC cough medicines 
that can utilize new flavors and sensations to enhance the 
placebo effect.
Fig. 5  List of ingredients of modern over-the-counter cough medicine 
(Benylin Mucus Cough Max Honey & Lemon Flavor 100  mg/5  ml 
Syrup) as detailed in summary of product characteristics (SmPC) of 
medicine
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